Anti-CD19/CD20 chimeric antigen receptor T cell therapy - Juventas Cell Therapy
Alternative Names: CD19/CD20 CAR-T cell therapy - Juventas Cell Therapy; CD19/CD20 chimeric antigen receptor T-cell therapy - Juventas Cell TherapyLatest Information Update: 12 Oct 2020
At a glance
- Originator Juventas Cell Therapy
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Non-Hodgkin's lymphoma